Bicocca Open Archive

Logo unimib boa
GORI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.661
EU - Europa 4.435
AS - Asia 1.774
SA - Sud America 16
Continente sconosciuto - Info sul continente non disponibili 11
AF - Africa 6
OC - Oceania 3
Totale 17.906
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.396
SE - Svezia 749
IT - Italia 743
IE - Irlanda 728
CN - Cina 662
SG - Singapore 588
DE - Germania 510
RU - Federazione Russa 485
UA - Ucraina 424
HK - Hong Kong 251
GB - Regno Unito 226
CA - Canada 225
FI - Finlandia 149
AT - Austria 117
VN - Vietnam 99
DK - Danimarca 82
TR - Turchia 72
FR - Francia 62
RO - Romania 45
IN - India 43
BE - Belgio 39
MX - Messico 29
ID - Indonesia 23
NL - Olanda 20
IR - Iran 14
PL - Polonia 14
CZ - Repubblica Ceca 11
EU - Europa 9
BR - Brasile 8
CH - Svizzera 6
JP - Giappone 6
HN - Honduras 5
BZ - Belize 4
ES - Italia 4
PT - Portogallo 4
BG - Bulgaria 3
CL - Cile 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AR - Argentina 2
AU - Australia 2
EE - Estonia 2
EG - Egitto 2
GR - Grecia 2
KR - Corea 2
ML - Mali 2
PH - Filippine 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BS - Bahamas 1
BY - Bielorussia 1
CO - Colombia 1
EC - Ecuador 1
IL - Israele 1
JM - Giamaica 1
JO - Giordania 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
SA - Arabia Saudita 1
SC - Seychelles 1
SI - Slovenia 1
TH - Thailandia 1
TZ - Tanzania 1
Totale 17.906
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.412
Woodbridge 1.344
Fairfield 1.231
Houston 1.015
Chandler 745
Dublin 713
Ashburn 634
Jacksonville 565
Wilmington 538
Singapore 480
Seattle 464
Cambridge 435
Frankfurt am Main 390
Dearborn 319
New York 305
Princeton 279
Hong Kong 249
Milan 220
Santa Clara 164
Nanjing 147
Altamura 133
Lawrence 133
Vienna 112
Lachine 110
Shanghai 105
Dong Ket 83
San Diego 72
Beijing 66
Ottawa 56
Andover 51
Boardman 50
Fremont 50
Nanchang 46
Galati 43
Hebei 41
Brussels 39
Los Angeles 38
Shenyang 38
Helsinki 35
London 32
Toronto 30
Norwalk 28
Falls Church 25
Florence 22
Hangzhou 20
Jakarta 20
Tianjin 19
Cuauhtémoc 18
Changsha 17
Edmonton 16
Guangzhou 16
Munich 16
Pune 16
Buffalo 15
Kunming 15
Jiaxing 14
Mountain View 14
Dallas 13
Rome 13
Chicago 11
Jinan 11
Kiev 10
Loreto 10
Detroit 9
Ningbo 9
San Mateo 9
Washington 9
Zhengzhou 9
Turin 8
Bari 7
Brescia 7
Clearwater 7
Lissone 7
Redmond 7
Romola 7
Amsterdam 6
Auburn Hills 6
Brno 6
Kilburn 6
Monza 6
San Giuliano Milanese 6
Vercelli 6
Hanoi 5
Laurel 5
Phoenix 5
San Francisco 5
Taizhou 5
Tegucigalpa 5
Belize City 4
Carate Brianza 4
Enterprise 4
Hounslow 4
Huizen 4
Lamezia Terme 4
Lanzhou 4
Leawood 4
Nürnberg 4
Piacenza 4
Polska 4
Stockholm 4
Totale 13.586
Salva come PNG Salva come JPEG
Nome #
Characterizing non-tuberculous mycobacteria infection in bronchiectasis 291
Specific immunosuppressive role of nanodrugs targeting calcineurin in innate myeloid cells 243
Similar success rates but lower incidence of telaprevir-related rash in HIV/HCV coinfected as compared to HCV-monoinfected patients treated with triple anti-HCV therapy 231
Effects of autologous stem cell transplantation in HIV: searching for the origins of viral replication in settings of profound CD4(+) T cell depletion 224
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 221
Comment on "Management of infections in cirrhotic patients: Report of a consensus conference" S Fagiuoli et al. [Dig Liver Dis 2014;46:204-212] 220
Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: The IMMUNEF clinical trial 218
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 211
The CCR5Δ32 allele is not a major predisposing factor for severe H1N1pdm09 infection 209
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 203
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 198
HIV testing: A must for patients with inflammatory bowel disease 197
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 194
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 190
Primary Whipple disease of the Central Nervous System presenting with rhombencephalitis 187
A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: Worth the risk? 184
miRNA-218 targets lipin-1 and glucose transporter type 4 genes in 3T3-L1 cells treated with lopinavir/ritonavir 181
Brachial and central blood pressure in HIV-infected subjects 179
A case of classic neuromyelitis optica (Devic's syndrome) triggered by pegylated-interferon α 176
Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response 175
Focal bone lesions in hiv-positive patient treated with tenofovir 174
Impact of orotracheal intubation and mechanical ventilation on the microbiota of the lung in the development of Ventilator- Associated Pneumonia 174
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: Results of the "cOPA" pilot randomized trial 174
Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy 173
ECMO: An alternative support for acute respiratory failure caused by tuberculosis? 173
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 173
Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice 171
Ultrasonographic backscatter of the carotid artery wall in patients with HIV infection: a pilot study 169
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 169
Metabolic syndrome in human immunodeficiency virus-positive subjects: prevalence, phenotype, and related alterations in arterial structure and function 168
Unmasking tuberculosis in the era of antiretroviral treatment 165
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 165
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen 165
Influence of hospitalization upon diagnosis on the risk of tuberculosis clustering 164
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 163
Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients 163
Neurocognitive Impairment in HIV-Infected Naïve Patients with Advanced Disease: The Role of Virus and Intrathecal Immune Activation 163
Combination versus sequential monotherapy in chronic HBV infection: A mathematical approach 161
KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy 161
Use of CXCR4-antagonist for haematopoietic stem cell mobilization in HIV-infected patients with haematological malignancies 159
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count 158
Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program 154
Strategies to limit immune-activation in HIV patients 154
Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis c coinfection: Data from the ICONA foundation cohort 150
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 150
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: Results of a 3-year cohort study 149
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 149
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 148
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy 147
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort 146
Mycobacterium tuberculosis Beijing family: Analysis of the epidemiological and clinical factors associated with an emerging lineage in the urban area of Milan 146
Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals 145
HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: Results of a randomized phase II exploratory clinical trial 144
Characterization of immune failure by monocyte activation phenotypes in HIV-infected patients receiving antiretroviral therapy 144
Neurocognitive impairment in HIV infected naïve patients: the role of genetic polymorphisms, viral changes and intrathecal immune activation 142
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study 139
Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy 139
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 138
Re: The challenge of Clostridium difficile infection: Overview of clinical manifestations, diagnostic tools and therapeutic options 137
Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: A multilevel analysis 136
Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis 135
Antimicrobial therapy duration: A major matter in the management of severe infections 133
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 133
Beyond the gut bacterial microbiota: The gut virome 133
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects Data from the ICONA Foundation Cohort 133
Inflammatory cytokines drive CD4+ t-cell cycling and impaired responsiveness to interleukin 7: Implications for immune failure in HIV disease 131
Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study 131
Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure 131
Latent tuberculosis infection in psoriasis and other dermatological immunomediated diseases: A combined approach by QuantiFERON®-TB Gold and tuberculin skin tests 130
Combination antifungal therapy for invasive mold infections among pediatric patients with hematological malignancies: Data from a real-life case-series 130
Impact of previous ART and of ART initiation on outcome of HIV-associated tuberculosis 129
An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy 128
A case of mild pulmonary disease due to Mycobacterium shimoidei with a favorable outcome 127
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 125
Untargeted Mass Spectrometry Approach to Study SARS-CoV-2 Proteins in Human Plasma and Saliva Proteome 124
To the editor 124
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy 122
Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008 121
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 121
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: Relation with patient and cohort characteristics 120
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 118
The immunomodulatory nutritional intervention NR100157 reduced CD4 + T-cell decline and immune activation: A 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study) 117
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 115
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 114
Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme 114
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 114
The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: Results from the Italian MASTER Cohort 113
Immunity to human immunodeficiency virus (HIV) infection 112
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 111
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 111
Exogenous reinfection of tuberculosis in a low-burden area 110
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons 110
Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: The D:A:D study 110
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort 109
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 109
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011 109
Letter: Antibiotic dose adjustment in patients with advanced liver disease 107
Fully immunocompetent CD8+ T lymphocytes are present in autologous haematopoietic stem cell transplantation recipients despite an ineffectual T-helper response 106
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: A MASTER cohort study 106
Mycobacterial interspersed repetitive-unit-variable-number tandem-repeat analysis and Beijing/W family of Mycobacterium tuberculosis 105
Totale 15.175
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.929
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.929
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.362 0 0 0 0 281 410 389 281 391 235 271 104
2020/20212.067 151 222 233 223 145 119 184 151 162 212 89 176
2021/20221.509 40 103 212 146 73 135 61 124 72 118 116 309
2022/20232.909 369 803 233 291 188 471 31 167 210 28 72 46
2023/20242.086 43 72 97 81 283 552 427 80 145 49 35 222
2024/20251.744 285 525 358 211 365 0 0 0 0 0 0 0
Totale 18.850